Endocrine Late Effects Following Cancer Treatment

 

Endocrine Late Effects Following Cancer Treatment: A Comprehensive Review

Dr Neeraj Manikath , claude.ai

Abstract

The dramatic improvement in cancer survival rates over the past four decades has created a growing population of cancer survivors at risk for treatment-related late effects. Endocrine dysfunction represents one of the most common and clinically significant categories of late effects, affecting multiple axes of the hypothalamic-pituitary system and peripheral endocrine organs. This review synthesizes current evidence on endocrine late effects following cancer therapy, with emphasis on recognition, screening, and management strategies relevant to internists caring for adult cancer survivors.

Introduction

Approximately 17 million cancer survivors currently live in the United States, with projections suggesting this number will exceed 22 million by 2030. As survival improves, the burden of treatment-related morbidity becomes increasingly apparent. Endocrine late effects occur in 20-50% of cancer survivors, depending on treatment modality, dose, and age at exposure. These complications may emerge months to decades after treatment completion, making long-term surveillance essential.

Understanding endocrine late effects requires familiarity with the mechanisms by which cancer therapies damage endocrine tissue: direct cytotoxic effects on glandular tissue, radiation-induced vascular damage, autoimmune phenomena, and hypothalamic-pituitary axis disruption. The internist's role encompasses screening, diagnosis, and lifelong management of these conditions.

Hypothalamic-Pituitary Dysfunction

Pathophysiology and Risk Factors

Radiation to the hypothalamic-pituitary region is the primary cause of central endocrine dysfunction. Doses as low as 18 Gy can cause pituitary damage, with risk increasing substantially above 30 Gy. The hypothalamus demonstrates greater radiosensitivity than the pituitary gland itself. Growth hormone (GH) deficiency typically appears first, followed sequentially by gonadotropin, ACTH, and TSH deficiencies—though this hierarchy is not absolute.

Brain tumor survivors, particularly those with craniopharyngiomas, optic pathway gliomas, and medulloblastomas, face the highest risk. Nasopharyngeal carcinoma patients receiving head and neck radiation also experience significant rates of hypopituitarism. Hematopoietic stem cell transplant (HSCT) recipients who received total body irradiation (TBI) demonstrate pituitary dysfunction in up to 50% of cases.

Growth Hormone Deficiency

Adult GH deficiency (AGHD) manifests with subtle but clinically meaningful symptoms: decreased exercise capacity, increased fat mass (particularly visceral adiposity), reduced bone mineral density, dyslipidemia, and diminished quality of life. Cardiovascular risk appears elevated in untreated AGHD.

Pearl: AGHD is vastly underdiagnosed in cancer survivors. Consider screening patients with cranial radiation ≥18 Gy who report unexplained fatigue, central adiposity, or reduced exercise tolerance.

Diagnostic approach: IGF-1 levels serve as an initial screening tool but lack sensitivity. Provocative testing with insulin tolerance test (ITT) or glucagon stimulation test provides definitive diagnosis. Peak GH <3-5 ng/mL indicates severe deficiency.

Management: GH replacement therapy in adults improves body composition, bone density, lipid profiles, and quality of life. Start with low doses (0.2-0.3 mg/day) and titrate based on IGF-1 levels, targeting the upper half of the age-adjusted normal range. Monitor for glucose intolerance and ensure adequate glucocorticoid replacement before initiating therapy.

Central Hypogonadism

Gonadotropin deficiency occurs in 20-30% of patients following hypothalamic-pituitary radiation. Symptoms include decreased libido, erectile dysfunction in men, and amenorrhea with vasomotor symptoms in women.

Oyster: Don't miss isolated LH deficiency in men presenting with low testosterone but preserved spermatogenesis—this pattern suggests hypothalamic rather than pituitary dysfunction and may be reversible with pulsatile GnRH therapy.

Hack: In premenopausal women with irregular menses post-radiation, measure anti-Müllerian hormone (AMH) to assess ovarian reserve and guide fertility counseling. Low AMH (<1.0 ng/mL) suggests limited fertility window requiring urgent reproductive planning.

Hormone replacement follows standard guidelines: testosterone therapy in men (aim for mid-normal levels) and estrogen-progesterone therapy in women until natural menopause age. Fertility preservation should be discussed before cancer treatment; however, some patients with partial gonadotropin deficiency may respond to ovulation induction or exogenous gonadotropins.

Central Hypothyroidism

Central hypothyroidism affects 10-20% of patients receiving >30 Gy to the hypothalamic-pituitary region, typically emerging 5-10 years post-treatment. Unlike primary hypothyroidism, TSH may be low, normal, or even mildly elevated with concurrent low free T4.

Pearl: Free T4, not TSH, is the critical screening parameter in patients at risk for central hypothyroidism. TSH cannot be used to guide dosing—adjust levothyroxine to maintain free T4 in the upper half of the normal range.

Central Adrenal Insufficiency

ACTH deficiency is less common but potentially life-threatening if unrecognized. Symptoms are often nonspecific: fatigue, nausea, hypotension, and hyponatremia. Unlike primary adrenal insufficiency, hyperkalemia and hyperpigmentation are absent.

Hack: Morning cortisol <3 μg/dL confirms adrenal insufficiency; >15 μg/dL essentially excludes it. Values between 3-15 μg/dL require provocative testing (ITT or high-dose cosyntropin test). Baseline ACTH adds diagnostic value: <10 pg/mL suggests central etiology.

Educate patients about stress dosing and provide emergency injection kits. Consider empiric stress-dose coverage during severe illness even in patients with borderline testing if clinical suspicion is high.

Thyroid Dysfunction

Primary Hypothyroidism

External beam radiation to the neck (Hodgkin lymphoma, head and neck cancers) causes primary hypothyroidism in 20-50% of patients. Risk correlates with radiation dose, field size, and follow-up duration. Median time to onset is 2-5 years, but cases emerge decades later.

Screening: Annual TSH measurement for life in all patients receiving neck radiation. Free T4 if TSH is abnormal or patient is symptomatic.

Radioiodine therapy for thyroid cancer nearly always results in hypothyroidism. Checkpoint inhibitor immunotherapy causes thyroid dysfunction in 5-10% of patients—typically an initial thyrotoxic phase followed by permanent hypothyroidism.

Thyroid Nodules and Cancer

Radiation exposure, particularly during childhood, substantially increases thyroid cancer risk (relative risk 5-15 for doses >20 Gy). The latency period is 5-10 years minimum, with risk persisting lifelong.

Pearl: Perform annual neck palpation and maintain low threshold for ultrasound evaluation. Nodules in radiation-exposed patients warrant more aggressive evaluation than in the general population.

Gonadal Dysfunction

Ovarian Failure

Alkylating agents (cyclophosphamide, busulfan, melphalan) and pelvic radiation cause dose-dependent ovarian damage. Age at treatment is the critical determinant of outcome—prepubertal ovaries demonstrate greater resilience than adult ovaries.

Cyclophosphamide doses >5 g/m² carry significant risk, while ovarian radiation >10 Gy typically causes permanent failure in adults. Acute ovarian failure manifests with amenorrhea and menopausal symptoms; more insidious is diminished ovarian reserve with shortened reproductive window.

Oyster: Young women with regular menses post-chemotherapy may still have markedly reduced fertility. Check FSH and AMH levels to assess reserve. Aggressive fertility counseling is warranted even with regular cycles if AMH is low.

Hormone replacement therapy is essential until natural menopause age to prevent premature bone loss, cardiovascular disease, and vasomotor symptoms. Extended-duration estrogen therapy may be appropriate given premature estrogen deprivation.

Testicular Dysfunction

Sertoli cells (supporting spermatogenesis) are more chemotherapy-sensitive than testosterone-producing Leydig cells. Azoospermia may occur with preserved testosterone production. Conversely, testicular radiation >20 Gy typically damages both cell populations.

Alkylating agents, platinum compounds, and testicular radiation are highest-risk treatments. Oligospermia may persist for years post-treatment, with variable recovery patterns.

Hack: Obtain baseline semen analysis 1-2 years post-treatment as a reference point. If azoospermic with normal testosterone and LH, Sertoli cell damage is isolated—fertility requires assisted reproductive techniques, but testosterone replacement is unnecessary. Elevated LH with low-normal testosterone indicates evolving Leydig cell failure requiring monitoring.

Metabolic Syndrome and Diabetes

Cancer survivors experience elevated rates of metabolic syndrome, diabetes, and cardiovascular disease. Multiple mechanisms contribute: direct pancreatic damage from radiation, steroid exposure, obesity from inactivity or cranial radiation affecting hypothalamic satiety centers, GH deficiency, and hypogonadism.

Abdominal radiation >15 Gy increases diabetes risk. HSCT recipients and those receiving prolonged corticosteroids face particular risk. Childhood cancer survivors have 1.8-fold increased diabetes risk compared to siblings.

Pearl: Screen cancer survivors annually with fasting glucose or HbA1c, particularly those with additional risk factors (obesity, hypertension, dyslipidemia). Implement aggressive lifestyle modification and early pharmacotherapy given elevated baseline cardiovascular risk.

Bone Health

Osteoporosis and fracture risk are substantially elevated in cancer survivors through multiple mechanisms: hypogonadism, GH deficiency, glucocorticoid exposure, direct bone marrow radiation, and chemotherapy-induced bone loss.

Young women with premature ovarian failure lose bone rapidly without hormone replacement. Similarly, androgen deprivation therapy for prostate cancer causes precipitous bone density decline. Hematopoietic stem cell transplant recipients experience multifactorial bone loss.

Screening approach: Obtain baseline DXA scan at end of treatment or within 1-2 years for high-risk patients (hypogonadism, glucocorticoid exposure ≥3 months, HSCT recipients). Repeat every 2-5 years based on initial results and risk factors.

Management: Ensure adequate calcium (1200 mg daily) and vitamin D (800-1000 IU daily) intake. Correct hormonal deficiencies. Consider bisphosphonate therapy for osteoporosis, though data in young cancer survivors are limited. Denosumab represents an alternative for patients with contraindications to bisphosphonates.

Hack: Young hypogonadal patients with osteopenia merit aggressive hormone replacement rather than immediate bisphosphonate therapy—optimizing sex hormones may obviate need for osteoporosis medications.

Checkpoint Inhibitor-Induced Endocrinopathies

The advent of immunotherapy has introduced novel endocrine complications. Checkpoint inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA-4) cause immune-mediated endocrinopathies in 5-15% of patients.

Thyroid dysfunction: Most common endocrine adverse event. Thyrotoxicosis followed by hypothyroidism is classic pattern.

Hypophysitis: More common with CTLA-4 inhibitors. Presents with headache, fatigue, nausea. May cause panhypopituitarism or isolated ACTH deficiency.

Type 1 diabetes: Rare but potentially presenting as diabetic ketoacidosis. Fulminant onset with low or absent C-peptide distinguishes from type 2 diabetes.

Primary adrenal insufficiency: Uncommon but life-threatening if missed.

Pearl: Maintain high clinical suspicion throughout immunotherapy course and for months afterward. Check TSH every 6-12 weeks during treatment. Investigate new symptoms promptly with comprehensive endocrine evaluation.

Most endocrinopathies are permanent requiring lifelong hormone replacement, though thyrotoxicosis may be transient. Corticosteroids treat hypophysitis but don't prevent permanent hormone deficiencies.

Screening Recommendations

Develop individualized surveillance plans based on treatment exposures:

Annual screening for all survivors:

• TSH for neck/cranial radiation or checkpoint inhibitors
• Clinical assessment for hypogonadism symptoms
• Fasting glucose and lipid panel

Additional screening based on exposures:

• Free T4 for hypothalamic-pituitary radiation (central hypothyroidism)
• Morning cortisol and/or ACTH stimulation for high-dose cranial radiation
• IGF-1 for cranial radiation ≥18 Gy (consider provocative testing if symptoms present)
• DXA scan for hypogonadism or extended glucocorticoid use
• Semen analysis for men exposed to alkylating agents or testicular radiation
• AMH for women with chemotherapy exposure desiring fertility information

Begin screening 1-2 years post-treatment completion, with frequency adjusted based on initial findings and risk stratification.

Conclusion

Endocrine late effects represent a major source of morbidity in cancer survivors, affecting quality of life, cardiovascular health, bone health, and fertility. The internist caring for cancer survivors must maintain vigilant long-term surveillance, as many endocrinopathies emerge years to decades post-treatment. Early recognition and appropriate hormone replacement improve outcomes and prevent complications. As cancer survivorship continues to expand, expertise in managing endocrine late effects becomes increasingly essential to comprehensive internal medicine practice.

Key Clinical Pearls

1. Central hypothyroidism requires free T4, not TSH, for screening and management
2. Adult GH deficiency is underdiagnosed—consider in fatigued survivors with cranial radiation
3. Annual thyroid surveillance (clinical and biochemical) is mandatory for all neck radiation recipients
4. Young women with regular menses post-chemotherapy may still have diminished ovarian reserve
5. Checkpoint inhibitor endocrinopathies are usually permanent despite stopping medication
6. Isolated low testosterone with normal LH suggests pituitary dysfunction, not primary hypogonadism
7. Screen for diabetes annually in abdominal radiation recipients and HSCT survivors

---

References

1. Sklar CA, Antal Z, Chemaitilly W, et al. Hypothalamic-Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(8):2761-2784.

2. Chemaitilly W, Cohen LE. Diagnosis of Endocrine Disease: Endocrine late-effects of childhood cancer and its treatments. Eur J Endocrinol. 2017;176(4):R183-R203.

3. van Santen HM, Chemaitilly W, Meacham LR, Tonorezos ES, Mostoufi-Moab S. Endocrine Health in Childhood Cancer Survivors. Pediatr Clin North Am. 2020;67(6):1171-1186.

4. Brabant G, Prank K, Ranft U, et al. Physiological regulation of circadian and pulsatile thyrotropin secretion in normal man and woman. J Clin Endocrinol Metab. 1990;70(2):403-409.

5. Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncol. 2018;4(2):173-182.

6. Molina GE, Basu SK, Mohan SK, Anjan VY. Checkpoint Inhibitor-Associated Endocrinopathies: A Review. JAMA Oncol. 2019;5(8):1294-1301.

7. Barkhoudarian G, Ku CJ, Joshi N, Frei B, Carrillo B, Blackman SM. Long-Term Endocrine and Metabolic Complications of Cranial Irradiation. Endocrinol Metab Clin North Am. 2020;49(4):689-705.

8. Hudson MM, Ness KK, Gurney JG, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013;309(22):2371-2381.

9. Molina GE, Basu SK. Endocrine Dysfunction Following Pediatric Cancer Treatment. Pediatr Clin North Am. 2020;67(6):1135-1149.

10. Mostoufi-Moab S, Seidel K, Leisenring WM, et al. Endocrine Abnormalities in Aging Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2016;34(27):3240-3247.